Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage

Janus kinase inhibitors (JAKis) represent a new strategy in rheumatoid arthritis (RA) therapy. Still, data directly comparing different JAKis are rare. In the present in vitro study, we investigated the immunomodulatory potential of four JAKis (tofacitinib, baricitinib, upadacitinib, and filgotinib)...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddig, Annika, Voss, Linda, Guttek, Karina, Roggenbuck, Dirk, Feist, Eugen, Reinhold, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036268/
https://www.ncbi.nlm.nih.gov/pubmed/33916057
http://dx.doi.org/10.3390/jcm10071431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036268/
https://www.ncbi.nlm.nih.gov/pubmed/33916057
http://dx.doi.org/10.3390/jcm10071431

Ejemplares similares